| Basics |
Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals Inc mainly develops targeted medicines for cancer and other proliferative diseases. The company focuses in hematology and oncology-based development pipeline of novel drug candidates.
|
| IPO Date: |
April 1, 2004 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$15.94M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.12 | 4.33%
|
| Avg Daily Range (30 D): |
$0.49 | 4.96%
|
| Avg Daily Range (90 D): |
$0.48 | 11.35%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.43M |
| Avg Daily Volume (30 D): |
.28M |
| Avg Daily Volume (90 D): |
2.98M |
| Trade Size |
| Avg Trade Size (Sh.): |
313 |
| Avg Trade Size (Sh.) (30 D): |
42 |
| Avg Trade Size (Sh.) (90 D): |
172 |
| Institutional Trades |
| Total Inst.Trades: |
50 |
| Avg Inst. Trade: |
$1.05M |
| Avg Inst. Trade (30 D): |
$.69M |
| Avg Inst. Trade (90 D): |
$.85M |
| Avg Inst. Trade Volume: |
.02M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.48M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
.05K |
|
|
| Financials |
| |
TTM |
Q2 2025 |
Q1 2025 |
|
Basic EPS
|
$506.25
|
$-.98
|
$
|
|
Diluted EPS
|
$506.25
|
$-.98
|
$
|
|
Revenue
|
$ .01M
|
$ M
|
$ M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -6.41M
|
$ -1.32M
|
$ -.08M
|
|
Operating Income / Loss
|
$ -10.36M
|
$ -1.32M
|
$ -5.04M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ M
|
$ M
|
$ M
|
|
PE Ratio
|
0.01
|
|
|
| Splits |
|
May 12, 2025:
1:16
|
|
Dec 18, 2023:
1:225
|
|
Apr 15, 2020:
1:20
|
|
May 31, 2016:
1:12
|
|
Aug 27, 2012:
1:7
|
|
|
|
